An Open-Label, Single-Arm, Multi-Center Study of TG-873870 for Treating Patients With Diabetic Foot Infections of Mild to Moderate Severity Associated With Gram-Positive Pathogens

Trial Profile

An Open-Label, Single-Arm, Multi-Center Study of TG-873870 for Treating Patients With Diabetic Foot Infections of Mild to Moderate Severity Associated With Gram-Positive Pathogens

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2015

At a glance

  • Drugs Nemonoxacin (Primary)
  • Indications Diabetic complications; Gram-positive infections; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Sponsors TaiGen Biotechnology
  • Most Recent Events

    • 12 Mar 2010 Primary endpoint 'Clinical response rate' has been met; results reported by TaiGen Biotechnology.
    • 22 Jan 2010 Additional trial location identified as reported by ClinicalTrials.gov.
    • 22 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top